Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
NovoCure Limited is a commercial-stage oncology company focused on the development and commercialization of Tumor Treating Fields (TTFields), a proprietary, non-invasive cancer therapy that uses alternating electric fields to disrupt cancer cell division. The company operates within the medical devices and oncology therapeutics industries, with its core offering designed to treat solid tumors. NovoCure’s primary revenue driver is the sale and rental of its TTFields systems, marketed under the Optune brand, which are prescribed for use alongside standard-of-care cancer treatments.
The company’s lead products include Optune for glioblastoma and Optune Lua for malignant pleural mesothelioma, both of which have received regulatory approvals in major markets. NovoCure’s unique positioning lies in its focus on a novel biophysical mechanism of action that is distinct from pharmaceuticals and biologics, supported by randomized clinical trial data. Founded in 2000, the company evolved from an early-stage research organization into a publicly listed commercial enterprise, completing its initial public offering in 2015 and expanding its clinical pipeline and global footprint thereafter.
Business Operations
NovoCure operates as a single-reportable-segment company focused on the research, development, manufacturing, and commercialization of TTFields therapy. Revenue is generated primarily through device usage fees associated with Optune and Optune Lua, which are typically reimbursed by public and private insurers in approved indications. The company controls its core TTFields technology, including device design, software, and field-delivery systems, while manufacturing is conducted through a combination of internal capabilities and third-party suppliers.
Operations are supported by a network of clinical education and patient support teams that assist with device adoption and adherence. NovoCure also conducts extensive clinical development programs, with ongoing or completed trials evaluating TTFields in additional indications such as lung, ovarian, pancreatic, and liver cancers. The company does not rely on material joint ventures for revenue generation but collaborates with academic institutions and clinical research organizations to execute its trials.
Strategic Position & Investments
NovoCure’s strategic direction centers on expanding the clinical indications and geographic adoption of TTFields therapy. Growth initiatives include advancing late-stage clinical trials in high-incidence solid tumors and pursuing regulatory approvals in additional markets. The company has invested significantly in clinical research and development rather than large-scale acquisitions, with capital allocation primarily directed toward expanding its pipeline and improving device usability.
The company has also invested in next-generation TTFields platforms and digital health capabilities to enhance treatment compliance and outcomes. While NovoCure does not maintain a broad portfolio of operating subsidiaries, its strategy emphasizes long-term value creation through intellectual property protection, physician education, and evidence generation. Data on returns from certain early-stage research investments is limited; where outcomes are not yet published, data inconclusive based on available public sources.
Geographic Footprint
NovoCure is legally domiciled in Jersey, with operational headquarters in Switzerland and the United States. The company has a significant presence in North America, which represents its largest revenue-generating region, driven by U.S. adoption of Optune for approved indications. It also maintains commercial operations across Europe, Israel, and parts of Asia, supported by regional offices and distributors.
Internationally, NovoCure’s footprint includes clinical trial activity and regulatory engagement in multiple countries, reflecting its strategy to broaden global access to TTFields therapy. Manufacturing, research, and administrative functions are distributed across the United States, Israel, and Europe, providing operational resilience and proximity to key markets.
Leadership & Governance
NovoCure is led by an executive team with experience in medical devices, oncology, and global healthcare commercialization. The company’s governance emphasizes scientific rigor, disciplined capital allocation, and long-term clinical value creation, with strategic decisions guided by clinical evidence and regulatory milestones.
Key executives include:
- Asaf Danziger – Chief Executive Officer
- Rodrigo Abreu – Chief Financial Officer
- William Doyle – Executive Chairman
- Ashley Cordova – Chief Operating Officer
- Eilon Kirson – Chief Medical Officer
The leadership team’s stated strategic vision focuses on establishing TTFields as a foundational modality in solid tumor oncology while maintaining compliance with regulatory standards and fostering sustainable growth through innovation and clinical validation.